BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/360/0.1/20.12.24

BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/360/0.1/20.12.24 Stock

DE000VD3R7P5

Market Closed - Boerse Frankfurt Warrants 01:54:22 2024-07-12 pm EDT
0.23 ^EUR	-20.69%

Current month	-36.11%
1 month	-42.50%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart BANK VONTOBEL/PUT/VERTEX PHARMACEUTICALS/360/0.1/20.12.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402	Jul. 11	MT
RBC Raises Price Target on Vertex Pharmaceuticals to $431 From $421, Keeps Sector Perform Rating	Jul. 09	MT
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment	Jul. 09	AQ
FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	Jul. 02	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-12	0.23	-20.69%
24-07-11	0.29	+31.82%
24-07-10	0.22	-12.00%
24-07-09	0.25	-10.71%
24-07-08	0.28	+3.70%

Real-time Boerse Frankfurt Warrants

Last update July 12, 2024 at 01:54 pm EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Vontobel
WKN	VD3R7P
ISIN	DE000VD3R7P5
Date issued	2024-04-09
Strike	360 $
Maturity	2024-12-20 (161 Days)
Parity	10 : 1
Emission price	1.43 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.07 €
Lowest since issue	0.207 €
Spread	0.04 €
Spread %	14.29%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company